Abstract:Once neglected in research and underappreciated in practice, there is renewed interest in bronchiectasis unrelated to cystic fibrosis. Bronchiectasis is a chronic lung disease characterised by chronic cough, sputum production and recurrent pulmonary exacerbations. It is diagnosed radiologically on high resolution computed tomography chest scan by bronchial dilatation (wider than the accompanying artery). The causes of bronchiectasis are diverse and include previous respiratory tract infections, chronic obstructive pulmonary disease, asthma, immunodeficiency and connective tissue diseases. A large proportion of cases are idiopathic, reflecting our incomplete understanding of disease pathogenesis. Progress in the evidence base is reflected in the 2017 European management guidelines and the 2015 update to the Australian guidelines. Effective airway clearance remains the cornerstone of bronchiectasis management. This should be personalised and reviewed regularly by a respiratory physiotherapist. There is now robust evidence for the long term use of oral macrolide antibiotics in selected patients to reduce exacerbation frequency. The routine use of long term inhaled corticosteroids and/or long-acting bronchodilators should be avoided, unless concomitant chronic obstructive pulmonary disease or asthma exists. The evidence for nebulised agents including hypertonic saline, mannitol and antibiotics is evolving; however, access is challenging outside tertiary clinics, and nebulising equipment is required. Smokers should be supported to quit. All patients should receive influenza and pneumococcal vaccination. Patients with impaired exercise capacity should attend pulmonary rehabilitation. There is an important minority of patients for whom aetiology-specific treatment exists. The prevalence of bronchiectasis is increasing worldwide; however, the burden of disease within Australia is not well defined. To this end, the Australian Bronchiectasis Registry began recruitment in 2016 and is interoperable with the European and United States bronchiectasis registries to enable collaborative research. The recent addition of a bronchiectasis diagnosis-related group to the Australian Refined Diagnostic Related Group classification system will allow definition of the disease burden within the Australian hospital system.

Mind the gap: challenges to overcome in airway clearance

Patient-managed interventions for adults with bronchiectasis: evidence, challenges and prospects

Airway clearance techniques and exercise in people with bronchiectasis: two different coins

Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)

Clinical perspectives in bronchiectasis management

Patients hospitalized with an infective exacerbation of bronchiectasis unrelated to cystic fibrosis: Clinical, physiological and sputum characteristics

Management of bronchiectasis in adults

Patient perspectives of airway clearance techniques in bronchiectasis

A systematic literature review of the clinical and socioeconomic burden of bronchiectasis

Research Advances and Clinical Management of Bronchiectasis: Chinese Perspective

Epidemiology of bronchiectasis

Cough in chronic lung disease: a state of the art review

Bronchiectasis in China: Present Situations and Challenges

Rethinking bronchiectasis as an inflammatory disease

Time to re-set our thinking about airways disease: lessons from history, the resurgence of chronic bronchitis / PBB and modern concepts in microbiology

Managing chronic cough in adults in primary care

The microbiome in bronchiectasis

Bronchiectasis: moving from an orphan disease to an unpleasant socioeconomic burden

Burden of refractory and unexplained chronic cough on patients' lives: a cohort study

Bronchiectasis Management in China, What We Can Learn from European Respiratory Society Guidelines

Bronchoscopic interventions for chronic bronchitis